GNG3: A Neurotransmitter Target with Potential for the treatment of various neurological diseases

Target Name: GNG3

NCBI ID: G2785

GNG3

GNG3: A Neurotransmitter Target with Potential for the treatment of various neurological diseases

GNG3 (Gabapentin-modified N-acetyl-L-tetrahydro-pyridine) is a drug target (or biomarker) that has been extensively studied for its potential in the treatment of various neurological disorders. GNG3 is a small molecule neurotransmitter that is derived from the natural compound gabapentin, which is an inhibitor of the brain's pain signaling system.

Gabapentin has been shown to have a wide range of therapeutic potential, including the treatment of epilepsy, bipolar disorder, and other neurological conditions. In addition to its potential therapeutic uses, GNG3 has also been the focus of intense research due to its potential as a drug target.

The GNG3 receptor is a G protein-coupled receptor that is expressed in a variety of tissues throughout the body, including the brain. Studies have shown that GNG3 is involved in a wide range of physiological processes, including pain signaling, neurotransmission, and cell survival.

One of the key features of GNG3 is its ability to modulate the activity of other proteins, particularly those involved in pain signaling. This is achieved through the interaction of GNG3 with G protein-coupled receptors, which are responsible for transmitting signals from the brain to other tissues.

GNG3 has been shown to interact with several different G protein-coupled receptors, including GPR75, GPR82, and GPR117. These interactions have led to the formation of GNG3-GPCR complexes, which have been shown to play important roles in pain signaling.

In addition to its potential as a drug target, GNG3 has also been the focus of intense research due to its potential as a biomarker. Studies have shown that GNG3 levels are significantly decreased in individuals with various neurological disorders, including epilepsy, bipolar disorder, and ALS.

In addition to its potential therapeutic and biomarker uses, GNG3 is also of interest to researchers due to its structural complexity. The 3D structure of GNG3 has been determined through a variety of techniques, including nuclear magnetic resonance and cryo-electron microscopy. This structure has provided insight into the molecular mechanisms that underlie GNG3's unique biology.

Overall, GNG3 is a drug target (or biomarker) that has the potential to revolutionize the treatment of a wide range of neurological disorders. Further research is needed to fully understand the mechanisms of GNG3's action and to develop safe and effective treatments.

Protein Name: G Protein Subunit Gamma 3

Functions: Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction

The "GNG3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNG3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets